Baxter shares are trading higher after the company announced a definitive agreement to divest its Vantive Kidney Care segment to Carlyle for $3.8 billion.
Portfolio Pulse from Benzinga Newsdesk
Baxter shares are trading higher following the announcement of a definitive agreement to divest its Vantive Kidney Care segment to Carlyle for $3.8 billion.
August 13, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baxter shares are trading higher after the company announced a definitive agreement to divest its Vantive Kidney Care segment to Carlyle for $3.8 billion.
The divestment of the Vantive Kidney Care segment for $3.8 billion is a significant move for Baxter, likely to improve its financial position and focus on core operations. This positive development has led to an increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100